NCT07233837 Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units
| NCT ID | NCT07233837 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Israelita Albert Einstein |
| Condition | Infection, Hospital |
| Study Type | INTERVENTIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2026-01-05 |
| Primary Completion | 2027-02-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 5,000 participants in total. It began in 2026-01-05 with a primary completion date of 2027-02-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Healthcare-associated infections (HAIs) remain a major problem in intensive care units (ICUs), driven by environmental contamination with multidrug-resistant organisms that persist despite routine manual cleaning. While hydrogen peroxide aerosolization and ultraviolet-C light devices have shown promise in reducing surface contamination, current evidence is inconsistent, mostly derived from single-center studies, and rarely linked to patient-centered outcomes. The investigators will conduct this cluster-randomized, crossover trial in 12 Brazilian ICUs. Each ICU will sequentially implement three strategies: (1) usual surface disinfection; (2) usual surface disinfection followed by hydrogen peroxide aerosolization at 7.9% concentration, applied through a dedicated device inside a protective tent during terminal cleaning of patient beds; and (3) usual surface disinfection followed by automated ultraviolet-C irradiation, also applied under the same tent to shield adjacent occupied beds. The primary outcome will be the antimicrobial utilization, measured as daily defined doses (DDD) of antimicrobials at the ICU level per 100 patient-days, with secondary outcomes including HAI incidence rate, environmental contamination with multidrug-resistant organisms, specific HAIs incidence rate (associated-ventilator pneumonia, central-line associated bloodstream infection, and catheter-associated urinary tract infection), and ICU length of stay costs.
Eligibility Criteria
Inclusion Criteria: * All patients aged 18 years and older who will be admitted to the participating ICUs Exclusion Criteria: * Patients under 18 years * ICUs that use peroxide hydrogen or ultraviolet light for surface disinfection as part of their protocol
Contact & Investigator
Antonio P Nassar Jr, PhD
PRINCIPAL INVESTIGATOR
Hospital Israelita Albert Einstein
Frequently Asked Questions
Who can join the NCT07233837 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Infection, Hospital. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07233837 currently recruiting?
Yes, NCT07233837 is actively recruiting participants. Contact the research team at antonio.nassar@einstein.br for enrollment information.
Where is the NCT07233837 trial being conducted?
This trial is being conducted at Barbalha, Brazil, Brasília, Brazil, Aparecida de Goiânia, Brazil, Passos, Brazil and 8 additional locations.
Who is sponsoring the NCT07233837 clinical trial?
NCT07233837 is sponsored by Hospital Israelita Albert Einstein. The principal investigator is Antonio P Nassar Jr, PhD at Hospital Israelita Albert Einstein. The trial plans to enroll 5,000 participants.